

24 July 2020

ASX Announcement

ADALTA TO PRESENT AT IRD INVEST INVESTOR CONFERENCE

MELBOURNE Australia, 24 July 2020: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce that CEO and Managing Director, Dr Tim Oldham, will present at the IRD Invest virtual investor conference on Wednesday, 29 July 2020 at 11.30 am AEST.

Dr Oldham will provide an update on the recent developments and future plans at AdAlta.

The event is free to attend and investors are invited to register, ahead of time via the following link: <http://adalta.com.au/adalta-present-29-july-ird-invest/>

Once the registration form is completed, investors will receive a confirmation email with detail on how to access the briefing.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
July 2020

Notes to Editors About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases.

AdAlta is conducting Phase 1 clinical studies for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare for diagnostic imaging agents against several drug targets, including Granzyme B.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product



candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <http://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 364 382
E: gabriella.hold@irdepartment.com.au